Replimune Group, Inc. 8-K

What Happened

• On June 26, 2026, Replimune Group, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma. The company furnished a news release announcing this development as Exhibit 99.1 to its Form 8-K (Item 7.01).

Key Details

• Date of announcement: June 26, 2026.
• Product: RP1 (vusolimogene oderparepvec) administered in combination with nivolumab.
• Regulatory action: FDA accepted the resubmitted BLA for review (resubmission accepted for review).
• Filing: News release furnished as Exhibit 99.1 to the Form 8-K; Form also includes interactive XBRL cover page (Item 9.01).

Why It Matters

• FDA acceptance of a BLA resubmission is an important regulatory milestone that starts the agency’s formal review process; it signals progress toward potential approval and commercialization if the review is successful.
• For investors, this development may affect Replimune’s clinical/regulatory timeline and long-term revenue potential for RP1 in advanced melanoma, but the filing itself does not guarantee approval and does not include new financial results or clinical data.